Hepatitis C virus vaccine development: old challenges and new opportunities  

作　　者：Dapeng Li Zhong Huang Jin Zhong 

机构地区：[1]Key Laboratory of Molecular Virology and Immunology,Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences [2]Institute Pasteur of Shanghai, Chinese Academy of Sciences

出　　处：《National Science Review》2015年第3期285-295,共11页国家科学评论（英文版）

基　　金：supported by grants from National Natural Science Foundation of China(81330039);National Basic Research Program of China(2015CB554300);Chinese National Science and Technology Major Project(2012ZX10002007-003);the CAS/SAFEA International Partnership Program for Creative Research Teams

摘　　要：Hepatitis C virus(HCV), an enveloped positive-sense single-stranded RNA virus, can cause chronic and end-stage liver diseases. Approximately 185 million people worldwide are infected with HCV. Tremendous progress has been achieved in the therapeutics of chronic hepatitis C thanks to the development of direct-acting antiviral agents(DAAs), but the worldwide use of these highly efective DAAs is limited due to their high treatment cost. In addition, drug-resistance mutations remain a potential problem as DAAs are becoming a standard therapy for chronic hepatitis C. Unfortunately, no vaccine is available for preventing new HCV infection. herefore, HCV still imposes a big threat to human public health, and the worldwide eradication of HCV is critically dependent on an efective HCV vaccine. In this review, we summarize recent progresses on HCV vaccine development and present our views on the rationale and strategy to develop an efective HCV vaccine.Hepatitis C virus (HCV), an enveloped positive-sense single-stranded RNA virus, can cause chronic and end-stage liver diseases. Approximately 185 million people worldwide are infected with HCV. Tremendous progress has been achieved in the therapeutics of chronic hepatitis C thanks to the development of direct-acting antiviral agents (DAAs), but the worldwide use of these highly effective DAAs is limited due to their high treatment cost. In addition, drug-resistance mutations remain a potential problem as DAAs are becoming a standard therapy for chronic hepatitis C. Unfortunately, no vaccine is available for preventing new HCV infection. Therefore, HCV still imposes a big threat to human public health, and the worldwide eradication of HCV is critically dependent on an effective HCV vaccine. In this review, we summarize recent progresses on HCV vaccine development and present our views on the rationale and strategy to develop an effective HCV vaccine.

关 键 词：hepatitis C virus VACCINE prophylactic vaccine therapeutic vaccine neutralizing antibody 

分 类 号：R512.63[医药卫生—内科学]